182 related articles for article (PubMed ID: 18667520)
1. A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.
Gainey MD; Manuse MJ; Parks GD
J Virol; 2008 Oct; 82(19):9369-80. PubMed ID: 18667520
[TBL] [Abstract][Full Text] [Related]
2. A simian virus 5 (SV5) P/V mutant is less cytopathic than wild-type SV5 in human dendritic cells and is a more effective activator of dendritic cell maturation and function.
Arimilli S; Alexander-Miller MA; Parks GD
J Virol; 2006 Apr; 80(7):3416-27. PubMed ID: 16537609
[TBL] [Abstract][Full Text] [Related]
3. Growth sensitivity of a recombinant simian virus 5 P/V mutant to type I interferon differs between tumor cell lines and normal primary cells.
Wansley EK; Dillon PJ; Gainey MD; Tam J; Cramer SD; Parks GD
Virology; 2005 Apr; 335(1):131-44. PubMed ID: 15823612
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring substitutions in the P/V gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha/beta interferon synthesis and cell death.
Wansley EK; Parks GD
J Virol; 2002 Oct; 76(20):10109-21. PubMed ID: 12239285
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induction and interferon signaling but not IFN-beta promoter induction by an SV5 P/V mutant are rescued by coinfection with wild-type SV5.
Wansley EK; Grayson JM; Parks GD
Virology; 2003 Nov; 316(1):41-54. PubMed ID: 14599789
[TBL] [Abstract][Full Text] [Related]
6. Virus growth and antibody responses following respiratory tract infection of ferrets and mice with WT and P/V mutants of the paramyxovirus Simian Virus 5.
Capraro GA; Johnson JB; Kock ND; Parks GD
Virology; 2008 Jul; 376(2):416-28. PubMed ID: 18456301
[TBL] [Abstract][Full Text] [Related]
7. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.
Fox CR; Parks GD
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343567
[TBL] [Abstract][Full Text] [Related]
8. Paramyxovirus-induced shutoff of host and viral protein synthesis: role of the P and V proteins in limiting PKR activation.
Gainey MD; Dillon PJ; Clark KM; Manuse MJ; Parks GD
J Virol; 2008 Jan; 82(2):828-39. PubMed ID: 17977969
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Fox CR; Parks GD
Viruses; 2019 May; 11(5):. PubMed ID: 31083335
[TBL] [Abstract][Full Text] [Related]
10. Role for the phosphoprotein P subunit of the paramyxovirus polymerase in limiting induction of host cell antiviral responses.
Dillon PJ; Parks GD
J Virol; 2007 Oct; 81(20):11116-27. PubMed ID: 17686837
[TBL] [Abstract][Full Text] [Related]
11. Exchange of P/V genes between two non-cytopathic simian virus 5 variants results in a recombinant virus that kills cells through death pathways that are sensitive to caspase inhibitors.
Dillon PJ; Wansley EK; Young VA; Alexander-Miller MA; Parks GD
J Gen Virol; 2006 Dec; 87(Pt 12):3643-3648. PubMed ID: 17098980
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
13. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling.
He B; Paterson RG; Stock N; Durbin JE; Durbin RK; Goodbourn S; Randall RE; Lamb RA
Virology; 2002 Nov; 303(1):15-32. PubMed ID: 12482655
[TBL] [Abstract][Full Text] [Related]
14. Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis.
Sun M; Rothermel TA; Shuman L; Aligo JA; Xu S; Lin Y; Lamb RA; He B
J Virol; 2004 May; 78(10):5068-78. PubMed ID: 15113888
[TBL] [Abstract][Full Text] [Related]
15. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
16. Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells.
Young DF; Chatziandreou N; He B; Goodbourn S; Lamb RA; Randall RE
J Virol; 2001 Apr; 75(7):3363-70. PubMed ID: 11238862
[TBL] [Abstract][Full Text] [Related]
17. Differential In Vitro Growth and Cell Killing of Cancer versus Benign Prostate Cells by Oncolytic Parainfluenza Virus.
Kedarinath K; Parks GD
Pathogens; 2022 Apr; 11(5):. PubMed ID: 35631014
[TBL] [Abstract][Full Text] [Related]
18. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
19. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
20. Differences in interferon sensitivity and biological properties of two related isolates of simian virus 5: a model for virus persistence.
Chatziandreou N; Young D; Andrejeva J; Goodbourn S; Randall RE
Virology; 2002 Feb; 293(2):234-42. PubMed ID: 11886243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
